NCT03723369

Brief Summary

Androgenetic alopecia is the most common type of hair loss in men, and affects approximately 50 percent of Caucasian men by age 50. The condition is characterized by the progressive loss of terminal hairs on the scalp in a characteristic distribution. The anterior scalp, mid scalp, temporal scalp, and vertex of the scalp are typical sites of involvement. "Male balding" and "male pattern hair loss" are additional terms used to refer to this condition. The aim of this study is to investigate the effect of microneedling in androgenic alopecia

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
7

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Oct 2018

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

October 24, 2018

Completed
5 days until next milestone

First Posted

Study publicly available on registry

October 29, 2018

Completed
1 day until next milestone

Study Start

First participant enrolled

October 30, 2018

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 30, 2019

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 30, 2019

Completed
Last Updated

January 2, 2020

Status Verified

December 1, 2019

Enrollment Period

1 year

First QC Date

October 24, 2018

Last Update Submit

December 30, 2019

Conditions

Dermatologic Disease

Outcome Measures

Primary Outcomes (1)

  • hair regrowth(7-point rating scale (-3 = greatly decreased, -2 = moderately decreased, -1 = slightly decreased, 0 = no change, +1 = slightly increased, +2 = moderately increased, +3 = greatly increased).)

    hair regrowth(7-point rating scale (-3 = greatly decreased, -2 = moderately decreased, -1 = slightly decreased, 0 = no change, +1 = slightly increased, +2 = moderately increased, +3 = greatly increased).)

    12weeks

Interventions

accupunctureDEVICE

accupuncture

Eligibility Criteria

Age20 Years - 60 Years
Sexmale(Gender-based eligibility)
Gender Eligibility Detailsandrogenic alopecia
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • \- androgenic alopecia patients

You may not qualify if:

  • infection, immune disorder, other dermatosis in treating areas

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

ShinKongHospital

Taipei, Taiwan

Location

MeSH Terms

Conditions

Skin Diseases

Condition Hierarchy (Ancestors)

Skin and Connective Tissue Diseases

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 24, 2018

First Posted

October 29, 2018

Study Start

October 30, 2018

Primary Completion

October 30, 2019

Study Completion

December 30, 2019

Last Updated

January 2, 2020

Record last verified: 2019-12

Data Sharing

IPD Sharing
Will not share

Locations

TW(1)